indications for semaglutide Lesson: Oral Semaglutide: A New GLP-1 Receptor Agonist Product the Treatment of Type 2 Diabetes Semaglutide- for weight loss in

Meta-analysis and the science of research synthesis

Food and Drug Administration (FDA) for the treatment of postherpetic neuralgia (nerve pain following shingles) and certain types of seizures (epilepsy), it is also commonly used off-label for other conditions such as general nerve pain (neuropathic pain), migraines, and restless leg syndrome

Related: Which Weight Loss Drug Is Right for Me

Global GLP-1 Receptor Agonist Market Size: Forecast (2026-2032) The Global GLP-1 Receptor Agonist Market size was valued at around USD 52.39 billion in 2025 and is projected to grow from USD 63.2 billion in 2026 to USD 78.4 billion by 2032

For additional background on these emerging areas of study, see our discussion of amylin protein as a therapeutic target in Alzheimers disease

Daniel Drucker, an endocrinologist at the University of Toronto who conducted some of the basic peptide research that helped lead to the development of GLP-1 drugs, told me